(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 December 2019 (26.12.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/243801 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2019/051699

(22) International Filing Date:
18 June 2019 (18.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1809946.5 18 June 2018 (18.06.2018) GB
1815694.3 26 September 2018 (26.09.2018) GB

(71) Applicants: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE). **OXFORD UNIVERSITY INNOVATION LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford OX2 0JB (GB). **THE UNIVERSITY OF ADELAIDE** [AU/AU]; Adelaide, SA 5005 (AU).

(72) Inventors: **DAVIES, Gareth Charles Glyndwr**; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **LEEDHAM, Simon**; c/o Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford Oxfordshire OX3 7BN (GB). **ZANNETTINO, Andrew**; 6 Domain Commons, Highbury, South Australia 5089 (AU). **CLARK, Kimberley**; 1/18 Audrey Street, Ascot Park, South Australia 5043 (AU). **HEWETT, Duncan**; 9 Darebin Street, Mile End, South Australia 5031 (AU). **PANAGOPOULOS, Vasilios**; Plympton, South Australia 5038 (AU).

(74) Agent: **J A KEMP LLP**; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER

Figure 1



(57) Abstract: The invention relates to an anti-GREM1 antagonist for use in a method for the treatment or prevention of a cancer.

WO 2019/243801 A1